期刊文献+

瑞舒伐他汀对冠状动脉慢血流患者冠状动脉贮备功能和超敏C反应蛋白的影响 被引量:5

Effects of rosuvastatin on coronary flow reserve and high-sensitivity C-reactive protein in patients with slow coronary flow
在线阅读 下载PDF
导出
摘要 目的:探讨长期瑞舒伐他汀治疗对冠状动脉慢血流患者冠脉贮备功能(CFR)和超敏C反应蛋白(hsCRP)的影响。方法:选择冠状动脉造影正常但存在冠脉慢血流的患者48例,所有患者随机分为试药组和对照组,对照组(22例)予常规治疗,试药组(26例)在常规治疗基础上加用瑞舒伐他汀20 mg/d,治疗期为6个月。治疗前后测定两组患者的血脂,hsCRP,利用腺苷负荷超声记录左前降支远端血流频谱评评价CFR。结果:经过6个月瑞舒伐他汀的治疗后,试药组总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)较对照组明显下降,[TC:(3.2±0.9)mmol/Lvs.(5.4±1.2)mmol/L,P<0.05;LDL-C:(2.1±0.7)mmol/L vs.(3.4±0.8)mmol/L,P<0.05]。hsCRP较对照组明显下降[(2.1±1.4)mg/L vs.(3.7±2.1)mg/L,P<0.05]。试药组静息冠脉血流速度(bCFV)较对照组和治疗前显著下降[(21±6)cm/s vs.(26±5)cm/s和(21±6)cm/s vs.(25±7)cm/s,P<0.05],而最大冠状动脉扩张状态hCFV较对照组和治疗前增加[(71±9)cm/s vs.(56±8)cm/s和(71±9)cm/s vs.(56±10)cm/s,P<0.05],冠状动脉血流储备CFR较对照组和治疗前明显增加[(3.2±0.6)cm/s vs.(2.1±0.5)cm/s和(3.2±0.6)cm/s vs.(2.2±0.4)cm/s,P<0.05)]。结论:冠状动脉慢血流患者经过瑞舒伐他汀治疗可以有效改善冠脉贮备功能。 AIM:To investigate the effect of rosuvastatin on coronary flow reserve(CFR) and high-sensitivity C-reactive protein(hsCRP) in patients with slow coronary flow.METHODS:A total of 48 patients with slow coronary flow but normal coronary angiography were included in this study.Patients were divided into rosuvastatin group(20 mg/day for 6 months,n=26) and control group(non-statin,n=22) and blood cholesterol and hsCRP were measured.Doppler coronary flow velocity and Doppler reserve measurement of distal left anterior descending artery were recorded at rest and adenosine infusion-induced hyperemia state.CFR was calculated by the ratio of maximal hyperemia and baseline peak diastolic coronary flow velocity(hCFV and bCFV) before and after rosuvastatin treatment.RESULTS:After treatment for 6 months,total cholesterol(TC) and low-density lipoprotein cholesterol(LDL-C) levels in rosuvastatin group were significantly lower than those in control group [TC:(3.2±0.9) mmol/L vs.(5.4±1.2) mmol/L,P0.05;LDL-C:(2.1±0.7) mmol/L vs.(3.4±0.8) mmol/L,P0.05].hsCRP in rosuvastatin group was significantly lower than in control group [(2.1±1.4) mg/L vs.(3.7±2.1) mg/L,P0.05].Compared with those in control group and rosuvastatin group before treatment,treatment for 6 months with rosuvastatin reduced bCFV [(21±6)cm/sec vs.(26±5)cm/sec and(21±6)cm/sec vs.(25±7)cm/sec,P0.05],increased hCFV [(71±9) cm/sec vs.(56±8) cm/sec and(71±9) cm/sec vs.(56±10) cm/sec,P0.05],and increased CFR [(3.2±0.6) cm/sec vs.(2.1±0.5) cm/sec and(3.2±0.6) cm/sec vs.(2.2±0.4) cm/sec,P0.05].CONCLUSION:Rosuvastatin may effectively improve coronary flow reserve and reduce hsCRP in patients with slow coronary flow.
出处 《心脏杂志》 CAS 2012年第1期71-74,共4页 Chinese Heart Journal
关键词 冠状动脉慢血流 瑞舒伐他汀 血流贮备功能 超敏C反应蛋白 slow coronary flow rosuvastatin coronary flow reserve high-sensitivity C-reactive protein
  • 相关文献

参考文献13

  • 1Mangieri E,Macchiarelli G,Ciavolella M,et al.Slow coronary flow:clinical and histopathological features in patients with othwise normal epicardial coronary arteries[J].Cathet Cardiovasc Diagn,1996,37(2):375-381.
  • 2Beltrame JF,Tumer SP,Leslie SL,et al.The angiographic and clinical benefits of mibefradil in the coronary slow phenomenon[J].J Am Coll Cardiol,2004,44(1):57-62.
  • 3Erdogan D,Caliskan M,Gullu H,et al.Coronary flow reserve is impaired in patients with slow coronary flow[J].Atherosclerosis,2007,191(1):168-174.
  • 4Beltrame JF,Limaye SB,Wuttke RD,et al.Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon[J].Am Heart J,2003,146(1):84-90.
  • 5Camsari A,Ozcan T,Ozer C,et al.Carotid artery intima-media thickness correlates with intravascular ultrasound parameters in pa-tients with slow coronary flow[J].Atherosclerosis,2008,200(2):310-314.
  • 6Kosar F,Ermis N,Yologlu S,et al.Vascular endothelial function in patients with slow coronary flow[J].Coron Artery Dis,2003,14(2):155-161.
  • 7Caliskan M,Erdogan D,Gullu H,et al.Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow[J].Clin Cardiol,2007,30(9):475-479.
  • 8樊瑛,杨树森,于江波,都金红,韩薇,甘润韬,王政,李为民,黄永麟.阿托伐他汀对冠状动脉血流缓慢患者冠状动脉血流储备的影响[J].中华心血管病杂志,2010,38(2):143-146. 被引量:23
  • 9Cakmak M,Tanriverdi H,Cakmak N,et al.Simvastatin may im-prove myocardial perfusion abnormality in slow coronary flow[J].Cardiology,2008,110(1):39-44.
  • 10刘艳红,张梅,刘玲梅,周欣,焦占全,李玉明,庞伟.短期应用辛伐他汀对大鼠缺血再灌注后心肌无复流的影响及其潜在机制[J].中华心血管病杂志,2008,36(8):729-734. 被引量:12

二级参考文献31

  • 1Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no fellow during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol, 2002, 283 : 1099-1107.
  • 2Celik T, Kurasaklioglu H, Iyisoy A, et al. The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction. Coron Artery Dis, 2005,16 : 321-326.
  • 3Pasceri V, Patti G,Nusca Aiet al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty ) study. Circulation, 2004,110 : 674-678.
  • 4Tavackoli S, Ashitkov T, Hu ZY, et al. Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels. Coron Artery Dis, 2004,15 : 53-58.
  • 5Patti G, Pasceri V, Colonna G, et aL Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized triaL J Am Coil Cardiol, 2007, 49: 1272-1278.
  • 6Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol, 2005, 96: 611-616.
  • 7Lefer AM, Campbell B,Shin YK,et al. Simvastatin preserves the ischemic-reperfused myocardium in nornaocholesterolemic rat hearts. Circulation, 1999,100 : 178-184.
  • 8Rabelink TJ, Luscher TF. Endothelial nitric oxide synthase: host defense enzyme of the endothelium? Arterioscler Thromb Vase Biol, 2006, 26: 267-271.
  • 9Becker BF, Kupatt C,Massoudy P,et al. Reactive oxygen species and nitric oxide in myocardial ischemia and reperfusion. Z Kardiol, 2000, 89 Suppl 9: IX/88-91.
  • 10Kis A, Yellon DM, Baxter GF. Role of nuclear factor-kappa B activation in acute ischaemia-reperfusion injury in myocardium. Br J Pharmacol, 2003,138 : 894-900.

共引文献33

同被引文献52

  • 1范群雄,张涛,唐雪梅,王小茅,胡勇.瑞舒伐他汀对老年高脂血症高敏C反应蛋白的影响及调脂疗效观察[J].实用心脑肺血管病杂志,2010,18(12):1789-1790. 被引量:11
  • 2毕京峰.瑞舒伐他汀钙胶囊人体生物等效性研究[J].中国成人医药教育论坛,2011,11 (4):13-15.
  • 3李斯瑞.舒伐他汀对人脐静脉平滑肌细胞增殖的影响[D].河北医科大学,2011:12-16.
  • 4蒋娟娟,田蕾,黄一玲,刘红,严岩,许莉,李一石.瑞舒伐他汀钙片中国人体的药动学[J].中国医院药学杂志,2007,27(11):1497-1500. 被引量:7
  • 5张红,熊玉卿.连续口服多剂量国产瑞舒伐他汀钙片的药动学[J].中国药学杂志,2007,42(23):1818-1821. 被引量:8
  • 6Baykan M,Baykan EC,Turan S.et aLAssessment of left ven- tricular function and Tei index by tissue Doppler imaging in patients with slow coronary flow[J].Echocardiography, 2009,26(10) : 1167-1172.
  • 7Sen T.Coronary slow flow phenomenon leads to ST elevation myocardial infarction[J].Korean Circ J,2013,43 (3):196- 198.
  • 8Rifai N, Ridker PM.High-sensitivity C-reactive-protein : a novel and promising marker of coronary heart disease[J]. Clin Chem, 2001,47 (3) : 403-411.
  • 9Diver DJ,Bier JD,Ferreira PE,et al.Clinical and arteriograph- ic characterization of patients with unstable angina without critical coronary arterial narrowing(from the TIMI-IUA Tri- al)[J].Am J Cardiol, 1994,74(6):531-537.
  • 10Mangieri E,Macchiarelli G,Ciavolella M,et al.Slow coronary flow:clinical and histopathological features in patients with otherwise normal epicardial coronary arteries[J].Cathet Car- diovasc Diagn, 1996,37(4) :375-381.

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部